Advances in the treatment of small vessel vasculitis

Rheumatic Disease Clinics of North America

Volumn 32, Issue 1, 2006, Pages 157-172

  Molloy, Eamonn S ^a,b   Langford, Carol A ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; ARTIFICIAL VENTILATION; BLADDER CARCINOMA; BLADDER DISEASE; BONE MARROW SUPPRESSION; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; COLITIS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INFECTION; INFERTILITY; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MICROSCOPIC POLYANGIITIS; MYELODYSPLASIA; NEPHROTOXICITY; PANCYTOPENIA; PLASMAPHERESIS; PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SMALL VESSEL VASCULITIS; SUBGLOTTIC STENOSIS; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS; CHURG-STRAUSS SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; PLASMAPHERESIS; WEGENER GRANULOMATOSIS;

EID: 33344467049     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2005.12.002     Document Type: Review

References (87)

1. C.A. Langford Wegener's granulomatosis: current and upcoming therapies Arthritis Res Ther 5 2003 180 191
2. E.W. Walton Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis) BMJ 34 1958 265 270
3. A.S. Fauci, and S.M. Wolff Wegener's granulomatosis: studies in eighteen patients and a review of the literature Medicine (Baltimore) 52 1973 535 561
4. A.S. Fauci, B.F. Haynes, and P. Katz Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years Ann Intern Med 98 1983 76 85
5. G.S. Hoffman, G.S. Kerr, and R.Y. Leavitt Wegener granulomatosis: an analysis of 158 patients Ann Intern Med 116 1992 488 498
6. E. Reinhold-Keller, J. Kekow, and A. Schnabel Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis Arthritis Rheum 37 1994 919 924
7. G.S. Hoffman, R.Y. Leavitt, and T.A. Fleisher Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide Am J Med 89 1990 403 410
8. L. Guillevin, J.F. Cordier, and F. Lhote A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis Arthritis Rheum 40 1997 2187 2198
9. K. de Groot, D. Adu, and C.O. Savage The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review Nephrol Dial Transplant 16 2001 2018 2027
10. R. Watts, L. Harper, and D. Jayne Translational research in autoimmunity: aims of therapy in vasculitis Rheumatology (Oxford) 44 2005 573 576
11. D. Jayne, N. Rasmussen, and K. Andrassy A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies N Engl J Med 349 2003 36 44
12. M.C. Sneller, G.S. Hoffman, and C Talar-Williams An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone Arthritis Rheum 38 1995 608 613
13. C.A. Langford, C. Talar-Williams, and M.C. Sneller Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis Arthritis Rheum 43 2000 1836 1840
14. G.S. Hoffman, R.Y. Leavitt, and G.S. Kerr The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate Arthritis Rheum 35 1992 1322 1329
15. K. de Groot, M. Muhler, and E. Reinhold-Keller Induction of remission in Wegener's granulomatosis with low dose methotrexate J Rheumatol 25 1998 492 495
16. J.H. Stone, W. Tun, and D.B. Hellman Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice J Rheumatol 26 1999 1134 1139
17. C.A. Langford, C. Talar-Williams, and K.S. Barron Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse Am J Med 114 2003 463 469
18. C.A. Langford, C. Talar-Williams, and K.S. Barron A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance Arthritis Rheum 42 1999 2666 2673
19. E. Reinhold-Keller, C.O. Fink, and K. Herlyn High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate Arthritis Rheum 47 2002 326 332
20. C. Talar-Williams, Y.M. Hijazi, and M.M. Walther Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 1996 477 484
21. R. Nowack, U. Gobel, and P. Klooker Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement J Am Soc Nephrol 10 1999 1965 1971
22. C.A. Langford, C. Talar-Williams, and M.C. Sneller Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis Arthritis Rheum 51 2004 278 283
23. B. Maes, M. Oellerich, and J.L. Ceuppens A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis Nephrol Dial Transplant 17 2002 923 926
24. J.S. Smolen, J.R. Kalden, and D.L. Scott Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group Lancet 353 1999 259 266
25. G.A. Bruyn, E.N. Griep, and K.J. Korff Leflunomide for active rheumatoid arthritis Lancet 353 1999 1883 [author reply 1883-4]
26. A.T. Chan, A. Bradlow, and J. McNally Leflunomide induced vasculitis-a dose-response relationship Rheumatology (Oxford) 42 2003 492 493
27. C. Metzler, C. Fink, and P. Lamprecht Maintenance of remission with leflunomide in Wegener's granulomatosis Rheumatology (Oxford) 43 2004 315 320
28. R. Birck, K. Warnatz, and H.M. Lorenz 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six month open-label trial to evaluate safety and efficacy J Am Soc Nephrol 14 2003 440 447
29. D.R. Jayne, H. Chapel, and D. Adu Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity QJM 93 2000 433 439
30. P.J. Clements, and J. Davis Cytotoxic drugs: their clinical application to the rheumatic diseases Semin Arthritis Rheum 15 1986 231 254
31. C. Thomas-Golbanov, and S. Sridharan Novel therapies in vasculitis Expert Opin Investig Drugs 10 2001 1279 1289
32. N.B. Allen, D.S. Caldwell, and J.R. Rice Cyclosporin A therapy for Wegener's granulomatosis Adv Exp Med Biol 336 1993 473 476
33. M. Haubitz, K.M. Koch, and R. Brunkhorst Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis Nephrol Dial Transplant 13 1998 2074 2076
34. W.H. Schmitt, E.C. Hagen, and I. Neumann Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients Kidney Int 65 2004 1440 1448
35. R.A. DeRemee, T.J. McDonald, and L.H. Weiland Wegener's granulomatosis: observations on treatment with antimicrobial agents Mayo Clin Proc 60 1985 27 32
36. H.L. Israel Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis Arch Intern Med 148 1988 2293 2295
37. J. Valeriano-Marcet, and H. Spiera Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim Arch Intern Med 151 1991 1649 1652
38. E. Reinhold-Keller, K. De Groot, and H. Rudert Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease QJM 89 1996 15 23
39. C.A. Stegeman, J.W. Tervaert, and P.E. de Jong Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group N Engl J Med 335 1996 16 20
40. P.J. Klemmer, W. Chalermskulrat, and M.S. Reif Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis Am J Kidney Dis 42 2003 1149 1153
41. M. Hasegawa, N. Kawamura, and M. Murase Efficacy of granulocytapheresis and leukocytapheresis for the treatment of microscopic polyangiitis Ther Apher Dial 8 2004 212 216
42. C.A. Langford, M.C. Sneller, and C.W. Hallahan Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis Arthritis Rheum 39 1996 1754 1760
43. M. Rottem, A.S. Fauci, and C.W. Hallahan Wegener granulomatosis in children and adolescents: clinical presentation and outcome J Pediatr 122 1993 26 31
44. G.S. Hoffman, C.K. Thomas-Golbanov, and J. Chan Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation J Rheumatol 30 2003 1017 1021
45. O. Jonasdottir, J. Petersen, and K. Bendtzen Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis APMIS 109 2001 781 786
46. E.L. Nassonov, M.Y. Samsonov, and G.P. Tilz Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis J Rheumatol 24 1997 666 670
47. B.R. Ludviksson, M.C. Sneller, and K.S. Chua Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10 J Immunol 160 1998 3602 3609
48. I.L. Noronha, C. Kruger, and K. Andrassy In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis Kidney Int 43 1993 682 692
49. V. Kindler, A.P. Sappino, and G.E. Grau The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection Cell 56 1989 731 740
50. A. Booth, L. Harper, and T. Hammad Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis J Am Soc Nephrol 15 2004 717 721
51. P. Bartolucci, J. Ramanoelina, and P. Cohen Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients Rheumatology (Oxford) 41 2002 1126 1132
52. P. Lamprecht, J. Voswinkel, and T. Lilienthal Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis Rheumatology (Oxford) 41 2002 1303 1307
53. J.H. Stone, M.L. Uhlfelder, and D.B. Hellmann Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety Arthritis Rheum 44 2001 1149 1154
54. A.D. Booth, H.J. Jefferson, and W. Ayliffe Safety and efficacy of TNFalpha blockade in relapsing vasculitis Ann Rheum Dis 61 2002 559
55. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis N Engl J Med 352 2005 351 361
56. R.S. Wallis, M.S. Broder, and J.Y. Wong Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 2004 1261 1265
57. D.H. Present, P. Rutgeerts, and S. Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
58. S.R. Targan, S.B. Hanauer, and S.J. van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med 337 1997 1029 1035
59. W.J. Sandborn, S.B. Hanauer, and S. Katz Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
60. P. Rutgeerts, G. D'Haens, and S. Targan Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
61. B. Scallon, A. Cai, and N. Solowski Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418 426
62. A.M. Reimold New indications for treatment of chronic inflammation by TNF-alpha blockade Am J Med Sci 325 2003 75 92
63. A. Lugering, M. Schmidt, and N. Lugering Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
64. M.E. Reff, K. Carner, and K.S. Chambers Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
65. D.R. Anderson, A. Grillo-Lopez, and C. Varns Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma Biochem Soc Trans 25 1997 705 708
66. R.A. Clynes, T.L. Towers, and L.G. Presta Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
67. R.J. Falk, and J.C. Jennette ANCA are pathogenic-oh yes they are! J Am Soc Nephrol 13 2002 1977 1979
68. C.G. Kallenberg, A. Rarok, and C.A. Stegeman New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis Autoimmun Rev 1 2002 61 66
69. M.C. Sneller Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 52 2005 1 5
70. U. Specks, F.C. Fervenza, and T.J. McDonald Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum 44 2001 2836 2840
71. P. Eriksson Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab J Intern Med 257 2005 540 548
72. K.A. Keogh, M.E. Wylam, and J.H. Stone Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis Arthritis Rheum 52 2005 262 268
73. J. Davson, J. Ball, and R. Platt The kidney in periarteritis nodosa Q J Med 17 1948 175 202
74. J.C. Jennette, R.J. Falk, and K. Andrassy Nomenclature of systemic vasculitides. Proposal of an international consensus conference Arthritis Rheum 37 1994 187 192
75. C.O. Savage, C.G. Winearls, and D.J. Evans Microscopic polyarteritis: presentation, pathology and prognosis Q J Med 56 1985 467 483
76. D. Adu, A.J. Howie, and D.G. Scott Polyarteritis and the kidney Q J Med 62 1987 221 237
77. H. Rodgers, J.A. Guthrie, and A.M. Brownjohn Microscopic polyarteritis: clinical features and treatment Postgrad Med J 65 1989 515 518
78. S.L. Hogan, P.H. Nachman, and A.S. Wilkman Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis J Am Soc Nephrol 7 1996 23 32
79. C.A. Langford, J.H. Klippel, and J.E. Balow Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity Ann Intern Med 129 1998 49 58
80. P.H. Nachman, S.L. Hogan, and J.C. Jennette Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis J Am Soc Nephrol 7 1996 33 39
81. G.S. Hoffman Wegener's granulomatosis Curr Opin Rheumatol 5 1993 11 17
82. M. Gayraud, L. Guillevin, and P. le Toumelin Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients Arthritis Rheum 44 2001 666 675
83. N. Tsurikisawa, M. Taniguchi, and H. Saito Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin Ann Allergy Asthma Immunol 92 2004 80 87
84. C. Metzler, B. Hellmich, and A. Gause Churg-Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment Clin Exp Rheumatol 22 2004 S52 S61
85. E. Tatsis, A. Schnabel, and W.L. Gross Interferon-alpha treatment of four patients with the Churg-Strauss syndrome Ann Intern Med 129 1998 370 374
86. C.C. Termeer, J.C. Simon, and E. Schopf Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement Arch Dermatol 137 2001 136 138
87. A. Reissig, M. Forster, and B. Mock Interferon-alpha treatment of the Churg-Strauss syndrome Dtsch Med Wochenschr 128 2003 1475 1478